TDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease

C Amador‐Ortiz, WL Lin, Z Ahmed… - Annals of Neurology …, 2007 - Wiley Online Library
C Amador‐Ortiz, WL Lin, Z Ahmed, D Personett, P Davies, R Duara, NR Graff‐Radford…
Annals of Neurology: Official Journal of the American Neurological …, 2007Wiley Online Library
Objective This study aimed to determine the frequency of frontotemporal lobar degeneration
with ubiquitinated inclusions (FTLD‐U) in the setting of hippocampal sclerosis (HpScl) and
Alzheimer's disease (AD) using immunohistochemistry for TAR DNA binding protein 43
(TDP‐43), a putative marker for FTLD‐U. Methods Initially, 21 cases of HpScl associated
with a variety of other pathological processes and 74 cases of AD were screened for FTLD‐
U with TDP‐43 immunohistochemistry. A confirmation study was performed on 93 additional …
Objective
This study aimed to determine the frequency of frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD‐U) in the setting of hippocampal sclerosis (HpScl) and Alzheimer's disease (AD) using immunohistochemistry for TAR DNA binding protein 43 (TDP‐43), a putative marker for FTLD‐U.
Methods
Initially, 21 cases of HpScl associated with a variety of other pathological processes and 74 cases of AD were screened for FTLD‐U with TDP‐43 immunohistochemistry. A confirmation study was performed on 93 additional AD cases. Specificity of TDP‐43 antibodies was assessed using double‐immunolabeling confocal microscopy, immunoelectron microscopy, and biochemistry.
Results
TDP‐43 immunoreactivity was detected in 71% of HpScl and 23% of AD cases. Double immunostaining of AD cases for TDP‐43 and phospho‐tau showed that the TDP‐43–immunoreactive inclusions were usually distinct from neurofibrillary tangles. At the ultrastructural level, TDP‐43 immunoreactivity in AD was associated with granular and filamentous cytosolic material and only occasionally associated with tau filaments. Western blots of AD cases showed a band that migrated at a higher molecular weight than normal TDP‐43 that was not present in AD cases without TDP‐43 immunoreactivity.
Interpretation
These results suggest that as many as 20% of AD cases and more than 70% of HpScl cases have pathology similar to that found in FTLD‐U. Whether this represents concomitant FTLD‐U or is analogous to colocalization of α‐synuclein and tau in AD, reflecting a propensity for codeposition of abnormal protein conformers, remains to be determined. Ann Neurol 2007;61:435–445
Wiley Online Library